OnQuality Pharmaceuticals Announces Presentations of OQL025 and OQL06x, at the AACR Annual Meeting
Newsroom




- Jan 5
OnQuality Pharmaceuticals Expands Part 2 of the NOVA-II Phase 2 Clinical Trial to China and India


- Nov 10, 2022
Targeted Oncology First Patient With VEGFRi-Associated Hand-Foot Skin Reaction Enrolled in NOVA-II

- Nov 9, 2022
Clinical Trials Arena I OnQuality enrols first subject in Phase II HFSR therapy trial


- Nov 8, 2022
OnQuality Pharmaceuticals Announces Enrollment of First Patient in Part 2 of the NOVA-II Phase 2


- Oct 14, 2022
OnQuality Pharmaceuticals to Present Two Posters at the 34th EORTC-NCI-AACR Symposium


- Aug 3, 2022
Behind Biotech I Hong Tang on Traditional Chinese Medicine and Targeted Cancer Supportive Therapy

- Jun 30, 2022
Hopkins Biotech Podcast I Hong Tang: Targeting the Common Side Effects of Cancer Therapies

- Jun 15, 2022
Fierce Biotech I After 3 years away, BIO marked by first-time handshakes

- Jun 1, 2022
BioSpectrum Asia I Our approach to managing the side effects of cancer therapy has evolved